Netherton Syndrome Market is expected to reach US$ 74.31 Mn by 2027

Biological Therapy Segment to Grow at Highest Pace in Netherton Syndrome Market during 2020–2027

According to The Insight Partners market research study of "Netherton Syndrome Market to 2027 – Global Analysis and Forecast by Therapy and Region," the global Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2020 to 2027. The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.

Netherton syndrome is a rare disorder characterized by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. The trichorrhexis invaginata indicates short and brittle hair, atopic diathesis represents susceptibility to allergy problems while ichthyosiform erythroderma encompasses red, inflamed, scaly skin. Netherton syndrome is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, although there is no family history of the disease, the syndrome is revealed even when two healthy parents that carry the mutated recessive gene have a child, which receives both copies of the recessive gene.

Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market. However, the biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. The growth of the market for the biological therapy segment is attributed to the increasing adoption of biological therapy due to its beneficial treatment outcomes.

Lifemax Laboratories, Inc.; Azitra, Inc.; Sixera Pharma Ab; Dermelix Biotherapeutics; Matrisys Bioscience; Quoin Pharmaceuticals Ltd.; and Krystal Biotech, Inc. are a few of the leading companies operating in the Netherton syndrome market. 

Netherton Syndrome Market, by Region, 2019 (%)

---

Netherton Syndrome Market to Grow at a CAGR of 20.3% to reach US$ 74.31 Million from 2020 to 2027

Download Free Sample

---

Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy (Keratolytic Agents, Oral and Topical Steroids and Retinoids, Topical Calcineurin Inhibitors, Radiation Therapy, and Biological Therapy), and Geography

The report segments the global Netherton syndrome market as follows:

By Therapy

• Keratolytic Agents
• Oral and Topical Steroids and Retinoid
• Topical Calcineurin Inhibitors
• Radiation Therapies
• Biological Therapies

By Geography

• North America
  • US
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
• Asia Pacific (APAC)
  • Japan